Last checked at 
Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Expanding strategic focus beyond biomarker discovery to development and commercialisation of laboratory tests, via its EpiSwitch platform. Company intends to make its biomarker arrays and 3D genome bioinformatics tools available to the R&D market and to work closely with big pharma to leverage the insights of the 3D genome knowledgebase it has built. Intends to offer precision medicine testing via partner laboratories, starting with a Covid-19 severity-of-response prognostic test.
"Adding additional commercial pathways allows us to take control of our own future, and significantly reduces some of the timelines to market and subsequent revenue generation. The pharma industry is always looking for innovative technologies that are reduced to practice, have been proven and can answer questions that existing molecular modalities cannot. I believe EpiSwitch can make a significant contribution and have a substantial impact on the field of precision medicine," says Chief Executive Jon Burrows.
Current stock price: 66.50 pence
Year-to-date change: down 44%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
